Reducing postoperative astigmatism
AssigneeSanten Pharmaceutical Co., Ltd.
InventorsMitsushi Hikida, Masaaki Hayashi
Life of this patent
Estimating the term…
Abstract
An object of the present invention is to find a drug which is useful for prevention of postoperative astigmatism. The present invention provides a preventive for postoperative astigmatism which comprises lactoferrin as an active ingredient. A preferred dosage form of the preventive for postoperative astigmatism is an ophthalmic solution, and a preferred concentration of lactoferrin is 0.1 to 1.0% (w/v).
Claims18
A method for reducing postoperative astigmatism by increasing the strength of a wound closure site comprising administering to the eyes of a patient after sclerocorneal incision or corneal incision, a pharmaceutically effective amount of lactoferrin in a concentration of 0.1 to 1.0% (w/v) to reduce postoperative astigmatism.
A method for reducing postoperative astigmatism by increasing the strength of a wound closure site comprising administering to the eyes of a patient that has undergone cataract surgery a pharmaceutically effective amount of lactoferrin in a concentration of 0.1 to 1.0% (w/v) to reduce postoperative astigmatism.
A method for reducing postoperative astigmatism by increasing the strength of a wound closure site comprising administering to the eyes of a patient that has undergone corneal transplantation a pharmaceutically effective amount of lactoferrin in a concentration of 0.1 to 1.0% (w/v) to reduce postoperative astigmatism.
Dependencies are inferred from the claim text.